Compare AbCellera Biologics Inc (ABCL) vs Fortinet Inc (FTNT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Fortinet Inc — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while Fortinet Inc trades at $155.89 (market cap $116.25B). The key difference: Fortinet Inc is far larger — about 49.5× AbCellera Biologics Inc's market cap. Which is the better fit depends on your goals.
| ABCL | FTNT | |
|---|---|---|
Market Cap | $2.35B | $116.25B |
Sector | Health | Technology |
52-Week High | $8.12 | $162.35 |
52-Week Low | $2.78 | $74.39 |
Enterprise Value | $1.99B | $113.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Fortinet (FTNT) trades at $158.67, up 1.55% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with revenue growing to $6.80B in 2025 and net income of $1.85B, though valuation multiples like P/E of 62.93 appear elevated. Recent earnings have consistently beaten expectations, and the company maintains robust profitability with a gross margin of 80.3%. News highlights include AI-driven security growth and upcoming Q2 2026 results announcement on July 29, 2026.
The outlook remains positive due to strong execution and cybersecurity demand, but high valuation and competitive pressures pose risks. Analyst consensus is mixed with a $115.53 price target below current levels, suggesting caution despite bullish technicals. Key risks include execution missteps and market volatility, while institutional sentiment leans neutral with 47.06% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
